Emerging Pharmacologic Strategies in the Management of Alcohol Withdrawal Syndrome: A Comparative Review of Randomized Clinical Trials

Background: Alcohol withdrawal syndrome (AWS) is a serious complication of alcohol use disorder (AUD), often requiring inpatient care and treatment with benzodiazepines. However, the associated risks of benzodiazepines highlight the need for safer, effective alternatives. Objective: This review evaluates recent clinical trials investigating adjunct and alternative pharmacologic treatments for AWS, including magnesium, intranasal oxytocin, dexmedetomidine, and calcium carbonate. Methodology: Findings from four randomized clinical trials were summarized: a multicenter study on magnesium supplementation (Airagnes et al.), a placebo-controlled trial on intranasal oxytocin (Melby et al.), a comparison of dexmedetomidine vs. diazepam (Mendez et al.), and a calcium carbonate intervention trial (Schuster et al.). Each study assessed AWS severity using clinical institute withdrawal assessment for alcohol, revised (CIWA-Ar) scores and other relevant clinical outcomes. Results: Magnesium supplementation showed no significant improvement in AWS symptoms or benzodiazepine use unless deficiency was present. Oxytocin demonstrated a trend toward reduced symptom severity and medication use, particularly in high alcohol consumers. Dexmedetomidine was superior to diazepam in sedation quality and hemodynamic stability. Calcium carbonate significantly reduced withdrawal symptoms and alcohol craving. Conclusion: While benzodiazepines remain the standard, alternative agents like dexmedetomidine, oxytocin, and calcium carbonate show promise in managing AWS. Larger and well-controlled studies are needed to validate their clinical utility.